RedHill Biopharma 的 Opaganib COVID-19 研究通過第二次獨立委員會審查
October 08, 2020 19:00 ET
|
RedHill Biopharma Ltd.
第二次排定的獨立安全監測委員會 (SMC) 審查一致建議不改變使用 opaganib 治療 COVID-19 的美國第 2 期研究--美國第 2 期研究已納入 75% 的患者，預計本季度稍後將公佈數據--與此同時，使用 opaganib 治療 COVID-19 的全球 2/3 期研究納入率迅速提高--計劃進行全球緊急使用授權申請，但須取得積極的臨床結果 以色列特拉維夫和北卡羅萊納州拉里格,...
RedHill Biopharma的Opaganib新冠肺炎研究通过独立委员会第二次审查
October 08, 2020 19:00 ET
|
RedHill Biopharma Ltd.
第二次计划内独立安全监测委员会（SMC）审查一致建议继续按原方案进行opaganib治疗新冠肺炎的美国2期研究--美国2期研究已招募到75%的患者，数据预计将在本季度末公布--与此同时，opaganib治疗新冠肺炎的全球2/3期研究的招募工作也进展迅速--全球紧急使用授权申请已在计划中，将等待积极临床结果 以色列特拉维夫和北卡罗来纳州罗利市, Oct. 09, 2020 (GLOBE...
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
October 08, 2020 10:30 ET
|
RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
Estudio de Opaganib COVID-19 de RedHill Biopharma pasa segunda revisión del Comité Independiente
October 08, 2020 08:00 ET
|
RedHill Biopharma Ltd.
Segunda revisión independiente preprogramada del Comité de Monitoreo de Seguridad (SMC) recomienda de forma unánime la continuación sin cambios del estudio de Fase 2 en Estados Unidos con opaganib en...
Opaganib COVID-19 da RedHill Biopharma Passa Segunda Análise do Comitê Independente
October 08, 2020 06:00 ET
|
RedHill Biopharma Ltd.
Segunda análise independente pré-agendada do Comitê de Monitoramento de Segurança (SMC) recomenda por unanimidade a continuação sem alteração do estudo de Fase 2 nos EUA com opaganib para COVID-19--O...
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
October 07, 2020 10:00 ET
|
RedHill Biopharma Ltd.
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 --The U.S. Phase 2...
RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences
October 06, 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Oct. 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
Бразилия одобряет исследование RedHill Biopharma фазы 2/3 COVID-19 с использованием Opaganib
September 25, 2020 01:00 ET
|
RedHill Biopharma Ltd.
Текущее глобальное исследование фазы 2/3 с пероральным введением opaganib у пациентов с тяжелой формой COVID-19 одобрено в Италии, Великобритании, России, Израиле, Мексике и Бразилии; На сегодняшний...
Brasilien genehmigt COVID-19-Studie der Phase II/III von RedHill Biopharma zu Opaganib
September 25, 2020 01:00 ET
|
RedHill Biopharma Ltd.
Die laufende weltweite Phase-II/III-Studie zu oral verabreichtem Opaganib bei Patienten mit schwerem COVID-19 ist in Italien, Großbritannien, Russland, Israel, Mexiko und Brasilien zugelassen. Bisher...
Le Brésil approuve l'étude de phase 2/3 évaluant l'opaganib pour le traitement de la maladie COVID-19
September 25, 2020 01:00 ET
|
RedHill Biopharma Ltd.
L'étude mondiale de phase 2/3 sur l'opaganib administré par voie orale chez des patients atteints d'une forme grave de la maladie COVID-19 est approuvée en Italie, au Royaume-Uni, en Russie, en...